Oxygen Biotherapeutics (NASDAQ:OXBT) has appointed a chief medical officer as the company prepares to move forward on mid-stage clinical trials for its experimental treatment for traumatic brain injury.
Dr. Charles L. Pamplin III, a retired U.S. army colonel, will oversee the phase 2b trials for Oxycyte, OxyBio’s lead product candidate which is being studied in trials in Israel and Switzerland. He will also oversee the Morrisville company’s preclinical work in the United States. Pamplin’s military experience figured in the hire. The company has talked about Oxycyte as a potential treatment for soldiers who suffer traumatic brain injury from battle.
“We believe Dr. Pamplin’s expertise in drug development, the drug approval process, investor outreach, and strategy, as well as his military ties will prove highly beneficial to the company immediately, and over the long term,” interim CEO and CFO Michael Jebsen said in a statement.
Pamplin was most recently the president of Medicines Oracle, a medical consultancy to the pharmaceutical industry. He has also worked at King Pharmaceuticals, where he was vice president, medical affairs; and Quintiles, where he managed several medical specialty programs including women’s health, urology and dermatology.
Pamplin is a licensed and board certified physician and a retired U.S. Army Colonel (Medical Corps), specializing in internal medicine, clinical pharmacology, business management and medical informatics. During his 22 year military career he contributed to the development of anti-malarial, antileishmanial, and chemical defense drugs and devices.
